NEW YORK (GenomeWeb News) – Rosetta Genomics today announced a deal with Precision Therapeutics to co-market Rosetta's miRview mets2 assay.
Under the terms of the agreement, the two firms will co-market in the US through July 30, 2014 the microRNA-based assay for the identification of the tumor of origin in cancers of unknown or uncertain primary (CUP). The deal includes certain pre-specified performance milestones.
Rosetta will continue to record all revenues for the test and will be responsible for sample collection, processing, and billing, it said. Precision is expected to launch its miRview mets2 co-marketing effort next month.
Other terms of the deal were not disclosed.
"With approximately 200,000 CUP patients in the US, we believe this co-marketing agreement will significantly enhance our reach and access to the physicians who diagnose cancer and who treat these patients, including pathologists and oncologists," Rosetta President and CEO Kenneth Berlin said in a statement.
In May, a designated Medicare contractor said that it would cover the assay. That decision, along with today's agreement, he added, "significantly strengthens our prospects for widespread market adoption and revenue growth."